Additionally, given the frequent presence of co-existing PIK3CA and RAS mutations in PTPN11-mutated human NSCLC samples, we hypothesized that targeting the PI3K or MAPK pathway could be a rational therapeutic approach in PTPN11-mutated NSCLC. This evidence concerns the gene PIK3CA and non-small cell lung carcinoma.